Figure 4


A
in vivo response
Responder
(67.4%)
Non-Responder
(77.8%)
adverse
(n=36)
intermediate
(n=43)
ELN risk
favorable
(n=16)
Non-Responder
(32.6%)
Responder
(62.5%)
Responder
(22.2%)
Non-Responder
(37.5%)


C
Vincristine
adverse
intermediate
favorable
Viability (AUC)
1.5
1.0
0.5
0.0
P = 0.0047
P = 0.08
P = 0.61
Non−Responder
Responder
Non−Responder
Responder
Non−Responder
Responder
in vivo response
Daunorubicin + Cytarabine
adverse
intermediate
favorable
Viability (VUC)
P = 0.014
P = 0.64
P = 0.85
in vivo response


B
In vivo response ~ ex vivo response
−log10(P value)
Vindesine
Cladribine
Vincristine
NSC 652287
Fludarabine
Crenolanib
Daunorubicin + Cytarabin
more resistant
n.s.
Mean viability difference


D
Vincristine
Daunorubicine + Cytarabine
Event−free survival probability
P = 0.02
P = 0.02
Time (in years)
Time (in years)
ex vivo sensitivity
less sensitive
sensitive


E
EFS ~ Vincristine
ex vivo resistance
adverse
intermediate
reference (favorable)
P = 0.02
P = 0.03
P = 0.2
Hazard ratio
EFS ~ Daunorubicin + Cytarabine
ex vivo resistance
adverse
intermediate
reference (favorable)
P = 0.04
P = 0.04
P = 0.3
Hazard ratio